The Oxford-Emergent Tuberculosis Consortium (OETC) Ltd
OETC Ltd is a joint venture between the University of Oxford and Emergent BioSolutions Inc, formed to develop the world’s most clinically advanced new tuberculosis vaccine – MVA85A.
MVA85A has been developed at the University’s Centre for Clinical Vaccinology and Tropical Medicine by Dr Helen McShane, working with Professor Adrian Hill.
OETC Ltd will manage the progression of the vaccine into a Phase IIb clinical trial in infants, which will take place at the Worcester trial site developed by the Aeras Global TB Vaccine Foundation. This trial will be supported by funding from both Aeras and the Wellcome Trust.
Isis Innovation Ltd has exclusively licensed the MVA85A vaccine and related technology to OETC Ltd. Under the joint venture agreement, Emergent BioSolutions has the rights to fully commercialise the vaccine, and Aeras will have the right to distribute the vaccine in the developing world for humanitarian purposes.